Researchers from Sun Yat-Sen University and MD Anderson Cancer Center have compared the proteins secreted by hepatocellular carcinoma (HCC) cells in responders and nonresponders to the anti-PD-1 antibody nivolumab.
Myc proto-oncogene protein (MYC) is a transcription factor that can modulate the transcription of several genes, and its overexpression has been found in many cancer types, including hepatocellular carcinoma (HCC). Its inhibition reverses tumorigenesis in vivo and it is a key therapeutic target in cancer. Stanford University scientists used CRISPR screening assays to identify several genes as downstream targets of MYC, including exportin-1 (XPO1), among others.
Researchers from Sirnaomics Inc. presented preclinical evaluation of novel intravenous polypeptide nanoparticle designed to simultaneously deliver two siRNAs, silencing TGF-β and COX-2.
Hepatocellular carcinoma (HCC) is characterized by a high rate of neovascularization, giving tumoral cells access to nutrients and contributing to disease progression and metastasis.
Therabionic GmbH received U.S. FDA humanitarian device exemption (HDE) for its P1 device for at-home treatment of hepatocellular carcinoma, which accounts for 80% of all liver cancers, in patients who have failed first- and second-line therapies.
Abbisko Therapeutics Co. Ltd. has received FDA clearance of its IND application for ABSK-012, a highly selective small-molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4), for advanced solid tumors.
Duo Oncology Inc. has been awarded a Small Business Technology Transfer grant by the National Cancer Institute (NCI) to support the development of DUO-307, a combination nanomedicine that delivers cytotoxic polymer conjugated gemcitabine (PGEM) and an immune modulating chemokine receptor type 2 antagonist (CCR2a) to tumor tissue.
Abbisko Therapeutics Co. Ltd. announced positive first-in-human data for its highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor, irpagratinib (ABSK-011), for treating advanced hepatocellular carcinoma with FGF19 overexpression, which is seen in roughly 30% of liver cancers.
Tempest Therapeutics Inc. has begun the hunt for a phase III partner to help reach the market with TPST-1120, the oral selective peroxisome-proliferator activated receptor-alpha (PPAR-alpha) antagonist that showed clinical superiority on multiple study endpoints in phase Ib/II as an add-on in first-line unresectable or metastatic hepatocellular carcinoma (HCC).
Researchers from Xiamen University and affiliated organizations have reported the discovery of nuclear hormone receptor NUR/77 (Nur77) modulators as potential candidates for the treatment of hepatocellular carcinoma (HCC).
